Business Context and Reporting Period
This Form 8-K is filed by Cerecor Inc. (noting a discrepancy in the request metadata which listed "Avalo Therapeutics, Inc.") for the reporting date of June 22, 2021. The filing details the entry into a material definitive agreement and other significant corporate events regarding the company's asset portfolio.
Key Financial Metrics and Agreements
The filing outlines specific financial terms for three distinct transactions:
- In-License (CERC-008): Cerecor entered an exclusive license with Sanford Burnham Prebys Medical Discovery Institute.
- Upfront fee: Mid-six digit amount.
- Annual maintenance fees: Mid-five digit amount.
- Milestone payments: Up to approximately $70 million based on development, regulatory, and sales milestones.
- Royalties: Tiered low-to-mid single-digit percentage on net sales and low double-digit percentage on sublicensing payments.
- Out-License (CERC-301): Rights assigned to Alto Neuroscience, Inc.
- Upfront payment: Mid-six digit amount.
- Future consideration: Development, regulatory, and sales milestones plus modest royalties.
- Assignment (CERC-406): Rights assigned to ES Therapeutics, LLC (affiliate of Armistice Capital).
- Upfront payment: Low-six digit amount.
- Future consideration: Development, regulatory, and sales milestones.
Note: The filing does not provide specific revenue, profit, cash flow, or debt figures for the period.
Material Changes
The primary material changes involve the strategic realignment of Cerecor's asset portfolio:
- Acquisition of Core Asset: Secured exclusive rights to the CERC-008 immune checkpoint program, expanding the company's core pipeline.
- Divestiture of Non-Core Assets: Outlicensed CERC-301 and assigned CERC-406 to third parties to focus resources on core programs.
- Related Party Transaction: The assignment of CERC-406 involved ES Therapeutics, an affiliate of a Cerecor director, approved under the company's related party transaction policy.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The transactions indicate a strategic shift to concentrate on the CERC-008 program while monetizing non-core assets. The company expects to file the full text of the Sanford Burnham Prebys License Agreement as an exhibit to its Form 10-Q for the quarter ending June 30, 2021, with certain terms redacted for confidential treatment.
Risks and Contingencies:
- Future cash flows are contingent upon achieving specific development, regulatory, and sales milestones, which are not guaranteed.
- The agreement with Sanford Burnham Prebys is subject to customary termination rights.
- Reliance on third-party partners (Alto Neuroscience and ES Therapeutics) for the development of divested assets.
Investor Verification Checklist
- Verify the exact dollar amounts for the "mid-six digit" and "low-six digit" upfront payments in the upcoming Form 10-Q.
- Review the specific milestones required to trigger the up to $70 million in payments for the CERC-008 program.
- Confirm the details of the related party transaction regarding ES Therapeutics and the affiliation with director Steven Boyd.
- Monitor the filing of the full Sanford Burnham Prebys License Agreement to understand redacted terms and royalty exclusions.